278.23
4.13 (1.51%)
| Previous Close | 274.10 |
| Open | 277.67 |
| Volume | 279,609 |
| Avg. Volume (3M) | 339,798 |
| Market Cap | 6,177,624,576 |
| Price / Sales | 20.79 |
| Price / Book | 9.46 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -123.38% |
| Operating Margin (TTM) | -57.79% |
| Diluted EPS (TTM) | -17.83 |
| Total Debt/Equity (MRQ) | 16.85% |
| Current Ratio (MRQ) | 5.91 |
| Operating Cash Flow (TTM) | -395.31 M |
| Levered Free Cash Flow (TTM) | -274.11 M |
| Return on Assets (TTM) | -25.56% |
| Return on Equity (TTM) | -50.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Madrigal Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | 3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.90 |
|
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 7.73% |
| % Held by Institutions | 108.21% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 460.00 (B. Riley Securities, 65.33%) | Buy |
| Median | 450.50 (61.92%) | |
| Low | 420.00 (Canaccord Genuity, 50.95%) | Buy |
| Average | 445.25 (60.03%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 316.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 02 May 2025 | 460.00 (65.33%) | Buy | 315.48 |
| Canaccord Genuity | 02 May 2025 | 420.00 (50.95%) | Buy | 315.48 |
| UBS | 02 May 2025 | 458.00 (64.61%) | Buy | 315.48 |
| JMP Securities | 24 Apr 2025 | 443.00 (59.22%) | Buy | 319.93 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 285.73 | - | 2,860 | 817,188 |
| BATE KENNETH | 285.73 | - | 715 | 204,297 |
| DALY JAMES M | 285.73 | - | 715 | 204,297 |
| FOUSE JACQUALYN A | 285.73 | - | 203 | 58,003 |
| FRIEDMAN PAUL A | 285.73 | - | 715 | 204,297 |
| LEVY RICHARD S | 285.73 | - | 715 | 204,297 |
| Aggregate Net Quantity | 5,923 | |||
| Aggregate Net Value ($) | 1,692,379 | |||
| Aggregate Avg. Buy ($) | 285.73 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FRIEDMAN PAUL A | Director | 20 Jun 2025 | Acquired (+) | 715 | 285.73 | 204,297 |
| DALY JAMES M | Director | 20 Jun 2025 | Acquired (+) | 715 | 285.73 | 204,297 |
| BAKER BROS. ADVISORS LP | Director | 20 Jun 2025 | Acquired (+) | 2,860 | 285.73 | 817,188 |
| FOUSE JACQUALYN A | Director | 20 Jun 2025 | Acquired (+) | 203 | 285.73 | 58,003 |
| LEVY RICHARD S | Director | 20 Jun 2025 | Acquired (+) | 715 | 285.73 | 204,297 |
| BATE KENNETH | Director | 20 Jun 2025 | Acquired (+) | 715 | 285.73 | 204,297 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |